文献速递呼吸危重症与机械通气

新生儿肺超声与肺表面活性物质给药:一项实用性多中心研究

Neonatal Lung Ultrasound and Surfactant Administration: A Pragmatic, Multicenter Study.
PubMed 文献 · Chest · 2021-07-19

LUS预测给药的AUC为0.86(95%CI 0.81-0.91),切点9时敏感度0.79、特异度0.83;LUS联合氧饱和度/FiO2比值预测效能最高(AUC 0.93,95%CI 0.89-0.97),且不受胎龄影响。

要点

  • LUS可可靠预测早产儿首次肺表面活性物质给药需求,不受胎龄影响。
  • LUS切点9时AUC 0.86,敏感度0.79、特异度0.83。
  • LUS联合氧饱和度/FiO2比值预测效能最高,AUC 0.93。

核心结论

  • LUS是决定首次肺表面活性物质给药的可靠标准,且不受胎龄影响。
  • LUS与氧饱和度/FiO2比值联合可显著提高预测表面活性物质需求的效能。

研究设计与样本

  • 采用受试者工作特征曲线评估LUS、氧饱和度/FiO2比值、FiO2和Silverman评分对表面活性物质给药的准确性。
  • 通过逻辑回归模型分析LUS和氧饱和度/FiO2比值对表面活性物质给药的同步预后价值,并校正胎龄。

主要发现

  • LUS预测首次表面活性物质给药的AUC为0.86(95%CI 0.81-0.91),切点9,敏感度0.79(95%CI 0.70-0.86),特异度0.83(95%CI 0.76-0.89),阳性预测值0.79(95%CI 0.71-0.87),阴性预测值0.82(95%CI 0.75-0.89),阳性似然比4.65(95%CI 3.14-6.89),阴性似然比0.26(95%CI 0.18-0.37)。
  • 不同胎龄组间无显著差异:25-27周AUC 0.91(95%CI 0.84-0.99),28-30周AUC 0.81(95%CI 0.72-0.91),31-33周AUC 0.88(95%CI 0.79-0.95)。
  • 接受一剂表面活性物质的婴儿在24小时内LUS显著下降。
  • 比较FiO2、氧饱和度/FiO2比值、LUS和Silverman评分作为表面活性物质给药标准时,仅Silverman评分表现显著较差。

关键数值与推荐

  • LUS切点9时,AUC 0.86(95%CI 0.81-0.91),敏感度0.79(95%CI 0.70-0.86),特异度0.83(95%CI 0.76-0.89)。
  • LUS联合氧饱和度/FiO2比值预测表面活性物质需求的AUC为0.93(95%CI 0.89-0.97)。

临床怎么用

  • LUS可作为决定早产儿首次肺表面活性物质给药的可靠标准,不受胎龄限制。
  • 联合氧饱和度/FiO2比值与LUS可提高预测表面活性物质需求的准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous research shows that a lung ultrasound score (LUS) can anticipate CPAP failure in neonatal respiratory distress syndrome. RESEARCH QUESTION: Can LUS also predict the need for surfactant replacement? STUDY DESIGN AND METHODS: Multicenter, pragmatic study of preterm neonates who underwent lung ultrasound at birth and those given surfactant by masked physicians, who also were scanned within 24 h from administration. Clinical data and respiratory support variables were recorded. Accuracy of LUS, oxygen saturation to Fio2 ratio, Fio2, and Silverman score for surfactant administration were evaluated using receiver operating characteristic curves. The simultaneous prognostic values of LUS and oxygen saturation to Fio2 ratio for surfactant administration, adjusting for gestational age (GA), were analyzed through a logistic regression model. RESULTS: Two hundred forty infants were enrolled. One hundred eight received at least one dose of surfactant. LUS predicted the first surfactant administration with an area under the receiver operating characteristic curve (AUC) of 0.86 (95% CI, 0.81-0.91), cut off of 9, sensitivity of 0.79 (95% CI, 0.70-0.86), specificity of 0.83 (95% CI, 0.76-0.89), positive predictive value of 0.79 (95% CI, 0.71-0.87), negative predictive value of 0.82 (95% CI, 0.75-0.89), positive likelihood ratio of 4.65 (95% CI, 3.14-6.89), and negative likelihood ratio of 0.26 (95% CI, 0.18-0.37). No significant difference was shown among different GA groups: 25 to 27 weeks' GA (AUC, 0.91; 95% CI, 0.84-0.99), 28 to 30 weeks' GA (AUC, 0.81; 95% CI, 0.72-0.91), and 31 to 33 weeks' GA (AUC, 0.88; 95% CI, 0.79-0.95), respectively. LUS declined significantly within 24 h in infants receiving one surfactant dose. When comparing Fio2, oxygen saturation to Fio2 ratio, LUS, and Silverman scores as criteria for surfactant administration, only the latter showed a significantly poorer performance. The combination of oxygen saturation to Fio2 ratio and LUS showed the highest predictive power, with an AUC of 0.93 (95% CI, 0.89-0.97), regardless of the GA interval. INTERPRETATION: LUS is a reliable criterion to administer the first surfactant dose regardless of GA. Its association with oxygen saturation to Fio2 ratio significantly improves the prediction power for surfactant need.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Raimondi F, Migliaro F, Corsini I, et al. Neonatal Lung Ultrasound and Surfactant Administration: A Pragmatic, Multicenter Study. Chest. 2021. PMID: 34293317. doi:10.1016/j.chest.2021.06.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。